A signature of immune function genes associated with recurrence-free survival in breast cancer patients

作者：Ascierto Maria Libera; Kmieciak Maciej; Idowu Michael O; Manjili Rose; Zhao Yingdong; Grimes Margaret; Dumur Catherine; Wang Ena; Ramakrishnan Viswanathan; Wang Xiang Yang; Bear Harry D; Marincola Francesco M; Manjili Masoud H^*

来源：Breast Cancer Research and Treatment, 2012, 131(3): 871-880.

DOI：10.1007/s10549-011-1470-x

• Breast cancer prognosis
• Tumor relapse
• Tumor microenvironment
• Immune response
• Neoadjuvant immunotherapy

The clinical significance of tumor-infiltrating immune cells has been reported in a variety of human carcinomas including breast cancer. However, molecular signature of tumor-infiltrating immune cells and their prognostic value in breast cancer patients remain elusive. We hypothesized that a distinct network of immune function genes at the tumor site can predict a low risk versus high risk of distant relapse in breast cancer patients regardless of the status of ER, PR, or HER-2/neu in their tumors. We conducted retrospective studies in a diverse cohort of breast cancer patients with a 1-5 year tumor relapse versus those with up to 7 years relapse-free survival. The RNAs were extracted from the frozen tumor specimens at the time of diagnosis and subjected to microarray analysis and real-time RT-PCR. Paraffin-embedded tissues were also subjected to immunohistochemistry staining. We determined that a network of immune function genes involved in B cell development, interferon signaling associated with allograft rejection and autoimmune reaction, antigen presentation pathway, and cross talk between adaptive and innate immune responses were exclusively upregulated in patients with relapse-free survival. Among the 299 genes, five genes which included B cell response genes were found to predict with %26gt; 85% accuracy relapse-free survival. Real-time RT-PCR confirmed the 5-gene prognostic signature that was distinct from an FDA-cleared 70-gene signature of MammaPrint panel and from the Oncotype DX recurrence score assay panel. These data suggest that neoadjuvant immunotherapy in patients with high risk of relapse may reduce tumor recurrence by inducing the immune function genes.

• 出版日期2012-2
• 单位NIH